LUXEMBOURG--(BUSINESS WIRE)--Auna S.A. ("Auna†or the "Company†), a leading healthcare services provider in Latin America with operations in Mexico, Peru, and Colombia, today announced the expansion of its insurance network in Mexico, significantly broadening its national footprint, as well as its intent to meet with debt and equity investors. Through partnerships with leading healthcare institutions, including Médica Sur in Mexico City, San Javier in Guadalajara, Simnsa in Tijuana, Centros Méd. ...

Financial Data and Key Metrics Changes - Consolidated FX neutral EBITDA grew by 5% year over year, indicating a recovery trajectory [6][17] - Adjusted EBITDA increased by 5% in FX neutral terms, while it decreased by 3% on an as-reported basis, with the margin remaining just over 22% [17][18] - Adjusted net income increased six times year over year, positively impacted by FX neutral EBITDA growth and a favorable FX variance [20] Business Line Data and Key Metrics Changes - Revenue in Mexico grew by 5% year over year, driven by higher average ticket prices despite fewer surgeries and emergency treatments [10] - Peru's healthcare services revenue grew by 5%, primarily due to increased surgery volumes and price increases [12] - Colombia's revenue remained flat year over year, but EBITDA increased by 9%, with a margin expansion of 1.4 percentage points [13][16] Market Data and Key Metrics Changes - Total capacity utilization decreased by 2.5 percentage points to 64%, mainly due to intentional growth management in Colombia [9] - In Mexico, capacity utilization declined due to lower surgery volumes and emergency visits, but improvements in physician recruitment are expected to aid recovery [9] - The oncology MLR in Mexico fell below 50%, reflecting efficiencies gained in pharmaceutical costs [9] Company Strategy and Development Direction - The company is focused on modernizing and integrating patient care to improve medical outcomes and drive long-term shareholder value [24] - There is an emphasis on risk-sharing models and diversifying the payer mix in Colombia to safeguard cash flows and operational stability [26] - The company remains optimistic about the recovery of volumes in Mexico and the potential of its oncology offerings [27] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges in Mexico and Colombia but believes operational adjustments will lead to improved performance [25] - The near-term growth outlook is uncertain due to trade and tariff issues in Mexico, but the Peru business continues to show strong growth potential [26] - Management expects volumes in Mexico to recover as physician relationships stabilize and align with the company's model [32][40] Other Important Information - The company refinanced over $62 million of short-term debt, improving its maturity profile [22] - Cash position decreased by 13% compared to the first quarter, but remains healthy [20] Q&A Session Summary Question: Update on Mexico's physician and supplier situation - Management reported stabilization in physician relationships and expects volume growth to improve, although the transition may take time [32][34] Question: Future of oncology MLR - Management indicated that MLR is expected to remain within a predictable range, with continuous cost containment and price adjustments [36] Question: New agreements in Colombia - Management confirmed progress in collections and a decrease in provisions, with an increase in risk-sharing contracts contributing to revenue growth [48] Question: Confidence in utilization increase in Mexico - Management believes the model is gaining traction and anticipates recovery in volumes despite current market softness [52] Question: Market share in Monterrey - Management stated that they represent over 30% of private sector beds in Monterrey and aim to increase their market share in high complexity services [56][58] Question: Normalization of effective tax rate - Management explained that the effective tax rate has stabilized due to consistent profit before tax and net profit, projecting a rate of around 35% to 38% going forward [60][62] Question: Negative free cash flow after interest costs - Management noted that organic free cash flow is expected to improve in the second half of the year, covering interest costs [62]

Financial Performance - Auna's consolidated revenue for Q2 2025 was S/1,094 million, a decrease of 2% year-over-year (YoY), but an increase of 4% on a foreign exchange neutral (FXN) basis[19] - Adjusted EBITDA for Q2 2025 was S/241 million, a decrease of 3% YoY, but an increase of 5% FXN, with a flat margin of 211% YoY[15,17,19] - Adjusted Net Income increased significantly YoY, showing a +6x increase[46] - The Leverage Ratio remained flat at 36x[17] Segment Performance - Healthcare Services Mexico revenue in Q2 2025 was S/274 million, a decrease of 9% YoY, but an increase of 5% in local currency[25] - Healthcare Services Peru & Oncosalud Peru revenue in Q2 2025 was S/474 million, an increase of 8% YoY[29] - Healthcare Services Colombia revenue in Q2 2025 was S/346 million, a decrease of 8% YoY, but remained flat in local currency[33] Debt and Cash Flow - The company successfully offered an additional $621 million in aggregate principal amount of senior secured notes due 2029 in May 2025[54] - End-of-period cash stood at S/175 million[50] - Consolidated debt was S/3,702 million (US$1,045 million)[54,58] Operational Metrics - Oncosalud Peru plan memberships increased by 10% YoY, reaching 1,388,579 members[19,101] - Total bed capacity across the healthcare network was 2,224 beds[19]

分组1 - Auna S.A. reported quarterly earnings of $0.33 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, and showing a significant increase from $0.03 per share a year ago, resulting in an earnings surprise of +153.85% [1] - The company posted revenues of $309 million for the quarter ended June 2025, which was 3% below the Zacks Consensus Estimate, but an increase from $292 million in the same quarter last year [2] - Auna S.A. has surpassed consensus EPS estimates three times over the last four quarters, but has only topped revenue estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 9% since the beginning of the year, while the S&P 500 has gained 9.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $330.33 million, and for the current fiscal year, it is $0.76 on revenues of $1.2 billion [7] 分组3 - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Auna S.A. currently holds a Zacks Rank 5 (Strong Sell), indicating expectations of underperformance in the near future [6]

Exhibit 99.1 Auna Announces 2Q25 Financial Results Adjusted EBITDA increases 5% FXN YoY with all segments contributing positively to quarterly results in their local currency Luxembourg, Aug 19, 2025 – Auna (NYSE: AUNA) ("Auna" or the "Company"), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, today announced financial results for the second quarter ended June 30, 2025 ("second quarter 2025" or "2Q25"). Financial results are expressed in Peruvian Soles ("S/" or ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Auna S.A. due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Auna S.A. is expected to report quarterly earnings of $0.13 per share, reflecting a year-over-year increase of +333.3% [3]. - Revenues are projected to be $314.67 million, which is a 7.8% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 13.04% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Auna S.A. aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - Auna S.A. currently holds a Zacks Rank of 5, making it challenging to predict an earnings beat [12]. - The company's surprise history shows it has beaten consensus EPS estimates two out of the last four quarters [14]. Market Reaction - The stock may experience upward movement if earnings exceed expectations, while a miss could lead to a decline [2]. - Historical performance indicates that even with an earnings beat, other factors can influence stock movement, making it essential to consider broader market conditions [15].

Core Insights - The article emphasizes the importance of identifying high-quality and mispriced investment opportunities, suggesting that great investment ideas should be intuitive and involve purchasing strong companies at favorable prices [1]. Group 1 - The focus is on the role of an investment analyst in uncovering valuable investment ideas, highlighting the necessity of thorough research and analysis [1]. - The article suggests that successful investments are characterized by a combination of quality companies and attractive pricing, which can lead to significant returns [1].

Financial Data and Key Metrics Changes - Auna reported consolidated revenue and EBITDA growth of only 41% on an FX neutral basis, which was lower than expected [7][8] - Net income was positive for the fifth consecutive quarter, indicating underlying financial stability despite operational setbacks [12][22] Business Line Data and Key Metrics Changes - Peru's operations outperformed, with a 10% increase in revenue driven by higher surgery volumes and improved pricing, while adjusted EBITDA increased by 19% [20][22] - In Mexico, revenues decreased by 4% and adjusted EBITDA by 5% on an FX neutral basis, attributed to operational setbacks and a challenging macroeconomic environment [15][22] Market Data and Key Metrics Changes - Capacity utilization in Peru increased by 4.4 percentage points year-over-year, while it decreased by 0.9 and 2.1 percentage points in Mexico and Colombia, respectively [14] - Colombia saw a 5% revenue increase in local currency, driven by risk-sharing models and diversification of the payer portfolio [21] Company Strategy and Development Direction - The company remains committed to transforming healthcare in Spanish-speaking Latin America through its value-based care model, with a focus on high complexity services [29] - Auna is diversifying its payer mix in Colombia to manage risk and stabilize cash flows, while also aiming to recover growth momentum in Mexico [30][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged operational setbacks in Mexico but expressed confidence in recovering growth momentum as corrective measures are implemented [8][12] - The company is optimistic about the long-term potential in Colombia and continues to focus on improving payment flows and cash cycle [30] Other Important Information - Auna's debt leverage remained unchanged, with a commitment to reach a midterm target of three times or less [12][28] - The company has maintained a solid cash position despite a 15% decrease in cash, generating PEN165 million of pretax operating cash flow [24][27] Q&A Session Summary Question: Update on Mexico's operations and transition to the Auna Way - Management clarified that the transition is necessary for long-term growth and efficiency, emphasizing the importance of aligning physician practices with the Auna model [35][36] Question: Update on Colombia's risk-sharing agreements - Management indicated that approximately 20% of revenues are now from risk-sharing models, with a target of 30% by the end of the year [37] Question: Guidance for Mexico's performance - Management refrained from providing specific guidance but expressed confidence in recovering growth in the coming quarters [48][49] Question: CapEx guidance and impairments in Colombia - CapEx is expected to remain at or below $50 million annually, with ongoing impairments in Colombia as part of a derisking strategy [52] Question: Acceptance of the Auna Way in Peru - Management noted that acceptance took several years in Peru, but they expect a quicker transition in Mexico due to lessons learned [63]

Financial Data and Key Metrics Changes - The company reported a disappointing quarter with revenue and EBITDA increasing by only 41% on an FX neutral basis [6][7] - Net income was positive for the fifth consecutive quarter, indicating underlying strength despite operational setbacks [12][22] Business Line Data and Key Metrics Changes - Peru's operations outperformed, with a 10% increase in planned memberships and a 19% increase in adjusted EBITDA [14][20] - In Mexico, revenues decreased by 4% and adjusted EBITDA by 5% on an FX neutral basis, attributed to operational setbacks and market softness [15][22] Market Data and Key Metrics Changes - Peru's total capacity utilization increased by 4.4 percentage points year over year, while Mexico and Colombia saw decreases of 0.9 and 2.1 percentage points, respectively [14][15] - Colombia experienced a 5% revenue increase in local currency, driven by risk-sharing models and diversification of the payer portfolio [21] Company Strategy and Development Direction - The company remains committed to transforming healthcare in Spanish-speaking Latin America through a value-based care model, with a focus on high complexity services [28][29] - The strategic direction includes recovering growth momentum in Mexico and expanding oncology capabilities [29][30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in Mexico due to the transition to the Auna Way, emphasizing the need for gradual implementation to avoid volume loss [33][41] - The outlook for Colombia is positive, with improved cash flows and a target to increase revenue from risk-sharing models to 30% by mid-next year [36][29] Other Important Information - The company maintained a healthy debt structure and is focused on reducing net debt leverage to a target of three times net debt to EBITDA [27] - CapEx is expected to remain at or below $50 million annually, with ongoing investments in the business [50][57] Q&A Session Summary Question: Update on Mexico's operations and transition to Auna Way - Management clarified that the transition is not a cleanup but a necessary transformation to align physician practices with the Auna Way, which is critical for growth in high complexity services [33][34] Question: Update on Colombia's risk-sharing agreements - Approximately 20% of revenues are now from risk-sharing models, with a target of 30% by the end of the year [36] Question: Details on operations in Mexico - The main source of lost volumes was due to close relationships between suppliers and physicians, but management is seeing early signs of recovery [41][42] Question: CapEx guidance and impairments in Colombia - CapEx is expected to remain consistent, and impairments in Colombia will continue as part of a derisking strategy [50] Question: Effective tax rate outlook - The effective tax rate is expected to stabilize around 38% this year, influenced by intercompany payments and deferred tax benefits [57] Question: Business development expenses in Mexico - Business development expenses were related to upfront payments to doctors and are nonrecurring [59][60] Question: Acceptance timeline for Auna Way in Peru - The acceptance in Peru took several years, while in Mexico, it is expected to be quicker due to lessons learned [61][62]

Company Performance - Auna S.A. reported quarterly earnings of $0.19 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.10 per share a year ago, representing an earnings surprise of 90% [1] - The company posted revenues of $281.43 million for the quarter ended March 2025, which was 5.95% below the Zacks Consensus Estimate and a decrease from $286.43 million in the same quarter last year [2] - Over the last four quarters, Auna S.A. has surpassed consensus EPS estimates two times and topped consensus revenue estimates only once [2] Market Comparison - Auna S.A. shares have increased by approximately 3.2% since the beginning of the year, outperforming the S&P 500's gain of 1.4% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $314.67 million, and for the current fiscal year, it is $0.77 on revenues of $1.23 billion [7] - The estimate revisions trend for Auna S.A. is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical Services industry, to which Auna S.A. belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]